[artículo] 
inJournal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 5 (Octubre) . - pp. 518-525

Título :	A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia
Tipo de documento:	texto impreso
Autores:	Ching Hua Lin, Autor ; Chao Chan Kuo, Autor ; Li Shiu Chou, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 518-525
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Combinación de fármacos antipsicóticos, Esquizofrenia, Haloperidol, Risperidona
Resumen:	Monotherapy is recommended for schizophrenia treatment, but the risk-benefit issue of antipsychotic drug combination (except for clozapine) remains unclear. Risperidone, an atypical antipsychotic drug, has a lower incidence of extrapyramidal syndrome but higher risks of prolactinemia and metabolic syndrome than haloperidol, a typical agent.
Link:	./index.php?lvl=notice_display&id=29424

[artículo] A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia [texto impreso] / Ching Hua Lin, Autor ; Chao Chan Kuo, Autor ; Li Shiu Chou, Autor . - 2022 . - pp. 518-525.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2010 - Vol. 30 - No. 5 (Octubre) . - pp. 518-525

Palabras clave:	Combinación de fármacos antipsicóticos, Esquizofrenia, Haloperidol, Risperidona
Resumen:	Monotherapy is recommended for schizophrenia treatment, but the risk-benefit issue of antipsychotic drug combination (except for clozapine) remains unclear. Risperidone, an atypical antipsychotic drug, has a lower incidence of extrapyramidal syndrome but higher risks of prolactinemia and metabolic syndrome than haloperidol, a typical agent.
Link:	./index.php?lvl=notice_display&id=29424